Meropenem and Hepatic cyst - a phase IV clinical study of FDA data

Summary:

Hepatic cyst is reported as a side effect among people who take Meropenem (meropenem), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Norvasc, and have Insomnia.

The phase IV clinical study analyzes which people have Hepatic cyst when taking Meropenem. It is created by eHealthMe based on reports of 33,250 people who have side effects when taking Meropenem from the FDA, and is updated regularly.

What is Meropenem?

Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.

What is Hepatic cyst?

Hepatic cyst is found to be associated with 776 drugs and 649 conditions by eHealthMe. Check the latest studies of Hepatic cyst.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

33,250 people reported to have side effects when taking Meropenem.
Among them, 18 people (0.05%) have Hepatic cyst.

Among these 18 people:

How long have people been on Meropenem when they have Hepatic cyst? *

What is the gender of people who have Hepatic cyst when taking Meropenem? *

female: 61.11 %
male: 38.89 %

What is the age of people who have Hepatic cyst when taking Meropenem? *

What are other drugs people take besides Meropenem? *

What are other side effects people have besides Hepatic cyst? *

Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 12 people, 66.67%
Thrombocytopenia (decrease of platelets in blood): 11 people, 61.11%
Malaise (a feeling of general discomfort or uneasiness): 9 people, 50.00%
Aspartate Aminotransferase Increased: 8 people, 44.44%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 8 people, 44.44%
Atelectasis (partial or complete collapse of the lung): 8 people, 44.44%
Splenomegaly (enlargement of spleen): 8 people, 44.44%
Pleural Effusion (water on the lungs): 8 people, 44.44%
Ascites (accumulation of fluid in the abdominal cavity): 8 people, 44.44%
Melaena (the passage of black, tarry stools): 8 people, 44.44%

What are the existing conditions these people have? *

Back Pain: 10 people, 55.56%
Insomnia (sleeplessness): 10 people, 55.56%
Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 7 people, 38.89%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 6 people, 33.33%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 27.78%
Fever: 4 people, 22.22%
Hepatic Cyst Infection: 3 people, 16.67%
Blood Potassium Decreased: 3 people, 16.67%
Chills (felling of cold): 3 people, 16.67%
Constipation: 3 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Meropenem and have Hepatic cyst?

- Check whether Hepatic cyst is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Meropenem:

Meropenem (33,295 reports)

Hepatic cyst treatments and more:

Hepatic cyst (5,071 reports)

Browse all side effects of Meropenem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic cyst:

Hepatic cyst (776 drugs)

Browse all the conditions that are associated with Hepatic cyst:

Hepatic cyst (649 conditions)

Related publications that referenced our studies

Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on meropenem (the active ingredients of Meropenem) and Meropenem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.